CN117860874A - Pharmaceutical composition of recombinant human coagulation factor VIIa - Google Patents
Pharmaceutical composition of recombinant human coagulation factor VIIa Download PDFInfo
- Publication number
- CN117860874A CN117860874A CN202410278314.1A CN202410278314A CN117860874A CN 117860874 A CN117860874 A CN 117860874A CN 202410278314 A CN202410278314 A CN 202410278314A CN 117860874 A CN117860874 A CN 117860874A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- polysorbate
- recombinant human
- human factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 104
- 108010054265 Factor VIIa Proteins 0.000 title abstract description 40
- 229940012414 factor viia Drugs 0.000 claims abstract description 46
- 208000032843 Hemorrhage Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims description 64
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 62
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 60
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 55
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 55
- 229920000053 polysorbate 80 Polymers 0.000 claims description 55
- 229940068968 polysorbate 80 Drugs 0.000 claims description 55
- 239000011780 sodium chloride Substances 0.000 claims description 31
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 30
- 108010008488 Glycylglycine Proteins 0.000 claims description 30
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 30
- 229930195725 Mannitol Natural products 0.000 claims description 30
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 30
- 229930006000 Sucrose Natural products 0.000 claims description 30
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 30
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims description 30
- 229940043257 glycylglycine Drugs 0.000 claims description 30
- 239000000594 mannitol Substances 0.000 claims description 30
- 235000010355 mannitol Nutrition 0.000 claims description 30
- 229930182817 methionine Natural products 0.000 claims description 30
- 239000005720 sucrose Substances 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 24
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 18
- 239000012931 lyophilized formulation Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 206010010356 Congenital anomaly Diseases 0.000 claims description 12
- 230000000740 bleeding effect Effects 0.000 claims description 12
- 208000031220 Hemophilia Diseases 0.000 claims description 9
- 208000009292 Hemophilia A Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 108010076282 Factor IX Proteins 0.000 claims description 6
- 108010054218 Factor VIII Proteins 0.000 claims description 6
- 102000001690 Factor VIII Human genes 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000013633 acquired hemophilia Diseases 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000034158 bleeding Diseases 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 238000001514 detection method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108010023321 Factor VII Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229940012413 factor vii Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 5
- 102100023804 Coagulation factor VII Human genes 0.000 description 4
- 229960004222 factor ix Drugs 0.000 description 4
- 229960000301 factor viii Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 3
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 229940099816 human factor vii Drugs 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical group OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940093561 novox Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present application belongs to the field of biological medicine, and specifically provides a pharmaceutical composition of recombinant human factor VIIa, provides a pharmaceutical composition or lyophilized preparation comprising the recombinant human factor VIIa, a preparation comprising the pharmaceutical composition or lyophilized preparation and application of the pharmaceutical composition or lyophilized preparation in preparing a medicament for preventing or treating hemorrhage in a subject.
Description
Technical Field
The application belongs to the field of biological medicine, and in particular relates to a pharmaceutical composition of recombinant human blood coagulation factor VIIa, a preparation method and application.
Background
Human Factor VII (FVII) is a vitamin K dependent serine protease that can either initiate the extrinsic pathway or participate in the intrinsic pathway by activating human factor IX. FVII is synthesized in the liver and secreted into the blood, where it circulates in the form of a single chain glycoprotein (zymogen) with a molecular weight of about 50,000 da. The zymogen FVII is proteolytically cleaved at position R152-I153 to form a double-stranded molecule linked by a disulfide bond, which is converted to the active form FVIIa.
Novox developed by Daneno and Norde corporation is recombinant human factor VIIa, similar in structure to human plasma-derived factor VIIa, and has been approved for the treatment of bleeding in congenital hemophilia patients with > 5 Bethesda Units (BU) of inhibitors of factor VIII or IX, congenital hemophilia patients predicted to have a high memory response to injection of factor VIII or IX, acquired hemophilia patients, congenital Factor VII (FVII) deficiency patients, and platelet-membrane glycoprotein IIb-IIa (GPIIb-IIa) and/or Human Leukocyte Antigen (HLA) antibodies and in patients with platelet inotropic disorders who have been or are now ineffective or poor in platelet infusion, as well as for the prevention of bleeding in surgical or invasive procedures.
In practice, it has been found that the stability of nootken is not ideal and that a recombinant human factor VIIa pharmaceutical composition with better stability needs to be developed to accommodate the requirements of mass production, transportation and long-term storage.
Disclosure of Invention
In one aspect, the present application provides a liquid pharmaceutical composition comprising recombinant human factor VIIa, glycylglycine, sodium chloride, calcium chloride dihydrate, mannitol, sucrose, methionine and 0.2-0.75 mg/mL polysorbate 80.
In some embodiments, the liquid pharmaceutical composition comprises 0.67-1 mg/mL recombinant human factor VIIa, preferably 0.67 mg/mL or 1 mg/mL.
In some embodiments, the liquid pharmaceutical composition comprises 0.88-1.32 mg/mL glycylglycine, preferably 0.88 mg/mL or 1.32 mg/mL.
In some embodiments, the liquid pharmaceutical composition comprises 1.56-2.34 mg/mL sodium chloride, preferably 1.56 mg/mL or 2.34 mg/mL.
In some embodiments, the liquid pharmaceutical composition comprises 0.98-1.47 mg/mL calcium chloride dihydrate, preferably 0.98 mg/mL or 1.47 mg/mL.
In some embodiments, the liquid pharmaceutical composition comprises 16.7-25 mg/mL mannitol, preferably 16.7 mg/mL or 25 mg/mL.
In some embodiments, the liquid pharmaceutical composition comprises 6.7-10 mg/mL sucrose, preferably 6.7 mg/mL or 10 mg/mL.
In some embodiments, the liquid pharmaceutical composition comprises 0.33-0.5 mg/mL methionine, preferably 0.33 mg/mL or 0.5 mg/mL.
In some embodiments, the liquid pharmaceutical composition comprises 0.2 mg/mL, 0.25 mg/mL, 0.3 mg/mL, 0.35 mg/mL, 0.4 mg/mL, 0.45 mg/mL, 0.5 mg/mL, 0.55 mg/mL, 0.6 mg/mL, 0.65 mg/mL, 0.7 mg/mL, or 0.75 mg/mL polysorbate 80.
In some embodiments, the liquid pharmaceutical composition comprises 0.67-1 mg/mL recombinant human factor VIIa, 0.88-1.32 mg/mL glycylglycine, 1.56-2.34 mg/mL sodium chloride, 0.98-1.47 mg/mL calcium chloride dihydrate, 16.7-25 mg/mL mannitol, 6.7-10 mg/mL sucrose, 0.33-0.5 mg/mL methionine, and 0.3-0.75 mg/mL polysorbate 80.
In some embodiments, the liquid pharmaceutical composition comprises 0.67-1 mg/mL recombinant human factor VIIa, 0.88-1.32 mg/mL glycylglycine, 1.56-2.34 mg/mL sodium chloride, 0.98-1.47 mg/mL calcium chloride dihydrate, 16.7-25 mg/mL mannitol, 6.7-10 mg/mL sucrose, 0.33-0.5 mg/mL methionine, and 0.3 mg/mL, 0.35 mg/mL, 0.4 mg/mL, 0.45 mg/mL, 0.5 mg/mL, 0.55 mg/mL, 0.6 mg/mL, 0.65 mg/mL, 0.7 mg/mL, or 0.75 mg/mL polysorbate 80.
In some embodiments, the liquid pharmaceutical composition comprises 0.67 mg/mL recombinant human factor VIIa, 0.88 mg/mL glycylglycine, 1.56 mg/mL sodium chloride, 0.98 mg/mL calcium chloride dihydrate, 16.7 mg/mL mannitol, 6.7 mg/mL sucrose, 0.33 mg/mL methionine, and 0.3-0.5 mg/mL polysorbate 80.
In some embodiments, the polysorbate 80 concentration is 0.3 mg/mL, 0.4 mg/mL, or 0.5 mg/mL.
In some embodiments, the liquid pharmaceutical composition comprises 0.67 mg/mL recombinant human factor VIIa, 0.88 mg/mL glycylglycine, 1.56 mg/mL sodium chloride, 0.98 mg/mL calcium chloride dihydrate, 16.7 mg/mL mannitol, 6.7 mg/mL sucrose, 0.33 mg/mL methionine, and 0.3 mg/mL, 0.4 mg/mL, or 0.5 mg/mL polysorbate 80.
In some specific embodiments, the liquid pharmaceutical composition comprises 0.67 mg/mL recombinant human factor VIIa, 0.88 mg/mL glycylglycine, 1.56 mg/mL sodium chloride, 0.98 mg/mL calcium chloride dihydrate, 16.7 mg/mL mannitol, 6.7 mg/mL sucrose, 0.33 mg/mL methionine, and 0.3 mg/mL polysorbate 80.
In some specific embodiments, the liquid pharmaceutical composition comprises 0.67 mg/mL recombinant human factor VIIa, 0.88 mg/mL glycylglycine, 1.56 mg/mL sodium chloride, 0.98 mg/mL calcium chloride dihydrate, 16.7 mg/mL mannitol, 6.7 mg/mL sucrose, 0.33 mg/mL methionine, and 0.4 mg/mL polysorbate 80.
In some specific embodiments, the liquid pharmaceutical composition comprises 0.67 mg/mL recombinant human factor VIIa, 0.88 mg/mL glycylglycine, 1.56 mg/mL sodium chloride, 0.98 mg/mL calcium chloride dihydrate, 16.7 mg/mL mannitol, 6.7 mg/mL sucrose, 0.33 mg/mL methionine, and 0.5 mg/mL polysorbate 80.
In some embodiments, the liquid pharmaceutical composition comprises 1. 1 mg/mL recombinant human factor VIIa, 1.32 mg/mL glycylglycine, 2.34 mg/mL sodium chloride, 1.47 mg/mL calcium chloride dihydrate, 25 mg/mL mannitol, 10 mg/mL sucrose, 0.5 mg/mL methionine, and 0.45-0.75 mg/mL polysorbate 80.
In some embodiments, the polysorbate 80 concentration is 0.45 mg/mL, 0.6 mg/mL, or 0.75 mg/mL.
In some embodiments, the liquid pharmaceutical composition comprises 1. 1 mg/mL recombinant human factor VIIa, 1.32 mg/mL glycylglycine, 2.34 mg/mL sodium chloride, 1.47 mg/mL calcium chloride dihydrate, 25 mg/mL mannitol, 10 mg/mL sucrose, 0.5 mg/mL methionine, and 0.45 mg/mL, 0.6 mg/mL, or 0.75 mg/mL polysorbate 80.
In some specific embodiments, the liquid pharmaceutical composition comprises 1. 1 mg/mL recombinant human factor VIIa, 1.32. 1.32 mg/mL glycylglycine, 2.34. 2.34 mg/mL sodium chloride, 1.47. 1.47 mg/mL calcium chloride dihydrate, 25 mg/mL mannitol, 10. 10 mg/mL sucrose, 0.5. 0.5 mg/mL methionine, and 0.45. 0.45 mg/mL polysorbate 80.
In some specific embodiments, the liquid pharmaceutical composition comprises 1. 1 mg/mL recombinant human factor VIIa, 1.32. 1.32 mg/mL glycylglycine, 2.34. 2.34 mg/mL sodium chloride, 1.47. 1.47 mg/mL calcium chloride dihydrate, 25 mg/mL mannitol, 10. 10 mg/mL sucrose, 0.5. 0.5 mg/mL methionine, and 0.6. 0.6 mg/mL polysorbate 80.
In some specific embodiments, the liquid pharmaceutical composition comprises 1. 1 mg/mL recombinant human factor VIIa, 1.32. 1.32 mg/mL glycylglycine, 2.34. 2.34 mg/mL sodium chloride, 1.47. 1.47 mg/mL calcium chloride dihydrate, 25 mg/mL mannitol, 10. 10 mg/mL sucrose, 0.5. 0.5 mg/mL methionine, and 0.75. 0.75 mg/mL polysorbate 80.
In some embodiments, the liquid pharmaceutical composition does not contain or comprises histidine. In some specific embodiments, the liquid pharmaceutical composition is histidine-free. In some specific embodiments, the liquid pharmaceutical composition further comprises histidine.
In some embodiments, the histidine is at a concentration of 10 mM.
In some embodiments, the liquid pharmaceutical composition has a pH of 6.0±0.5.
In some embodiments, the recombinant human factor VIIa comprises the sequences shown as SEQ ID NO. 2 and/or SEQ ID NO. 3.
In another aspect, the present application provides a lyophilized formulation obtained from the liquid pharmaceutical composition after lyophilization or the lyophilized formulation may be reconstituted to form the liquid pharmaceutical composition.
In another aspect, the present application provides a pharmaceutical composition comprising 1. 1 mg recombinant human factor VIIa, 1.32. 1.32 mg glycylglycine, 2.34. 2.34 mg sodium chloride, 1.47. 1.47 mg calcium chloride dihydrate, 25. 25 mg mannitol, 10 mg sucrose, 0.5. 0.5 mg methionine and 0.45-0.75 mg polysorbate 80.
In some embodiments, the polysorbate 80 is 0.45 mg, 0.6 mg, or 0.75 mg.
In some embodiments, the pharmaceutical composition comprises 1 mg recombinant human factor viia, 1.32 mg glycylglycine, 2.34 mg sodium chloride, 1.47 mg calcium chloride dihydrate, 25 mg mannitol, 10 mg sucrose, 0.5 mg methionine, and 0.45 mg, 0.6 mg, or 0.75 mg polysorbate 80.
In some specific embodiments, the pharmaceutical composition comprises 1 mg recombinant human factor viia, 1.32 mg glycylglycine, 2.34 mg sodium chloride, 1.47 mg calcium chloride dihydrate, 25 mg mannitol, 10 mg sucrose, 0.5 mg methionine, and 0.45 mg polysorbate 80.
In some specific embodiments, the pharmaceutical composition comprises 1 mg recombinant human factor viia, 1.32 mg glycylglycine, 2.34 mg sodium chloride, 1.47 mg calcium chloride dihydrate, 25 mg mannitol, 10 mg sucrose, 0.5 mg methionine, and 0.6 mg polysorbate 80.
In some specific embodiments, the pharmaceutical composition comprises 1 mg recombinant human factor viia, 1.32 mg glycylglycine, 2.34 mg sodium chloride, 1.47 mg calcium chloride dihydrate, 25 mg mannitol, 10 mg sucrose, 0.5 mg methionine, and 0.75 mg polysorbate 80.
In some embodiments, the pharmaceutical composition has a pH of 6.0±0.5.
In some embodiments, the recombinant human factor VIIa comprises the sequences shown as SEQ ID NO. 2 and/or SEQ ID NO. 3.
In another aspect, the present application provides the use of the liquid pharmaceutical composition, the lyophilized formulation or the pharmaceutical composition in the manufacture of a medicament for preventing or treating bleeding in a subject.
In another aspect, the present application provides the use of said liquid pharmaceutical composition, said lyophilized formulation or said pharmaceutical composition for the preparation of a medicament for the treatment of congenital hemophilia patients with inhibitors of factor viii or ix > 5 Bethesda Units (BU), congenital hemophilia patients expected to have a high memory response to injection of factor viii or factor ix, acquired hemophilia patients, congenital factor vii (vii) deficiency patients, or patients with platelet membrane glycoprotein iib-iia (GP iib-iia) and/or Human Leukocyte Antigen (HLA) antibodies and bleeding from patients with platelet weakness who were or are not currently ineffective or ill with platelet infusion, or for the prevention and treatment of bleeding from surgical or invasive procedures.
In some embodiments, the liquid pharmaceutical composition, lyophilized formulation, or pharmaceutical composition is administered to the subject by a parenteral route. In some embodiments, the liquid pharmaceutical composition, lyophilized formulation, or pharmaceutical composition is administered to the subject subcutaneously, intravenously, or intramuscularly. In some specific embodiments, the liquid pharmaceutical composition, lyophilized formulation, or pharmaceutical composition is administered to the subject intravenously.
In yet another aspect, the present application provides an article of manufacture comprising a vial containing the pharmaceutical composition.
In some embodiments, the article further comprises a prefilled needle containing a histidine solution.
In some embodiments, the article of manufacture further comprises instructions for administering recombinant human factor VIIa to a subject to prevent or treat bleeding.
In some embodiments, the dose of histidine is 1.55 mg. In some embodiments, the histidine is at a concentration of 10 mM.
The Tagg of the pharmaceutical composition provided by the application is more than 50 ℃, and the visible foreign matters and the polymers generated after shaking are few, and the polymers generated after long-term storage are few. The pharmaceutical compositions provided herein have improved stability, such as colloidal stability, shaking stability, and improvement in the stability of lyophilized finished products.
Detailed Description
Terminology
The term "recombinant human factor VIIa" refers to an active form of natural (wild-type) human factor VII prepared by recombinant techniques, recombinant human factor VIIa in this applicationSequence and marketed product nocarpus ® (recombinant human factor VIIa for injection, novo Nordisk A/S, denmark) the recombinant human factor VIIa has the same sequence. Natural human factor VII consists of 406 amino acid residues (SEQ ID NO: 1), and its active form human factor VIIa consists of two peptide chains (SEQ ID NO: 2 and SEQ ID NO: 3) linked by disulfide bonds.
SEQ ID NO. 1 sequence is shown below:
ANAFLXLRXLRPGSLXRXCKQCXQXXQSXXARXIFKTKLFWISYQCASQNGSQQLQQLICFCLPAFEGRNGKDQGQNEGQSDGTKRCSchschargyslassmallTYPCGKIPILEKRREQGRIVGGKVCPKGECPQLLVQLCGGTLIWVVSAAHVKVQNKNW NKUVLPQSRSRVQVQVIQVIPTYVPGQGTTQLLHQVQVTQVTQVQVQVQQVQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQV V, the process comprises, the process comprises, X is gamma-carboxyglutamic acid.
SEQ ID NO. 2 sequence is shown below:
ANAFLXXLRPGSLXRXCKXXQQXXXXARXIFKFKTKTKLFKLFKWisQASDSQNGGSCKQLQSQSiCOCCLPFCLPAFEGTKDQLICVNENGGCEQYCSDHTKRCSchrchNGUGYSLLADGVSCTTVEYPYPQCGKIPILEKRNASKPQGR the process comprises, the process comprises, X is gamma-carboxyglutamic acid.
SEQ ID NO. 3 sequence is shown below:
IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP。
the term "pharmaceutical composition" refers to a mixture of one or more active ingredients of the present application or pharmaceutical combinations thereof and pharmaceutically acceptable excipients.
The term "treatment" generally refers to an operation to obtain a desired pharmacological and/or physiological effect. The effect may be prophylactic according to the prevention of the disease or symptoms thereof, in whole or in part; and/or may be therapeutic in terms of partially or completely stabilizing or curing the disease and/or side effects resulting from the disease. As used herein, "treatment" encompasses any treatment of a disease in a patient, including but not limited to preventing the occurrence or recurrence of the disease, alleviating symptoms of the disease, reducing any direct or indirect pathological consequences of the disease, preventing metastasis of the disease, slowing the progression of the disease, ameliorating or alleviating the status of the disease, extending the frequency and duration of the asymptomatic phase, and resolving or improving the prognosis of the disease.
The terms "subject" or "patient" are used interchangeably herein. "subject" or "patient" includes any human or non-human animal. The term "non-human animal" includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, and rodents such as mice, rats, and guinea pigs. In some embodiments, the term "subject" or "patient" is a mammal. In some embodiments, the subject or patient is a mouse. In some embodiments, the subject or patient is a human.
The term "lyophilization", i.e. "freeze-drying", encompasses the process of removing a liquid from a dissolved or at least partially dissolved composition under conditions involving at least one step of cooling the dissolved/partially dissolved solution to ice followed by vacuum drying.
The terms "comprising" or "including" are to be construed in an open, non-exclusive sense, i.e. "including but not limited to.
As used herein, "about" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, depending in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" may mean within 1 or more than 1 standard deviation per the practice of the art. Alternatively, "about" may mean a range of up to + -5%, e.g., fluctuating within + -2%, within + -1%, or within + -0.5% of a given specific numerical range. When a particular value is given in the application or in the claims, unless otherwise indicated, the meaning of "about" is to be considered within the acceptable error of that particular value. In this context, all values relating to dose, time, step parameters or conditions are by default modified by "about" unless otherwise indicated.
Examples
Although the foregoing disclosure has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this disclosure that certain changes and modifications may be additionally made thereto without departing from the spirit or scope of the appended claims. The following examples are provided by way of illustration only and are not intended to be limiting. Those skilled in the art will readily recognize a variety of non-critical parameters that may be changed or modified to produce substantially similar results.
All reagents used in the examples, unless otherwise indicated, were commercially available.
The present disclosure also provides the following specific embodiments, but is not limited thereto:
embodiment 1. A liquid pharmaceutical composition comprising 0.67-1 mg/mL recombinant human factor VIIa, 0.88-1.32 mg/mL glycylglycine, 1.56-2.34 mg/mL sodium chloride, 0.98-1.47 mg/mL calcium chloride dihydrate, 16.7-25 mg/mL mannitol, 6.7-10 mg/mL sucrose, 0.33-0.5 mg/mL methionine and 0.3-0.75 mg/mL polysorbate 80.
Embodiment 2. The liquid pharmaceutical composition of embodiment 1, comprising 0.67 mg/mL recombinant human factor VIIa, 0.88 mg/mL glycylglycine, 1.56 mg/mL sodium chloride, 0.98 mg/mL calcium chloride dihydrate, 16.7 mg/mL mannitol, 6.7 mg/mL sucrose, 0.33 mg/mL methionine, and 0.3-0.5 mg/mL polysorbate 80.
Embodiment 3. The liquid pharmaceutical composition of embodiment 2, the concentration of polysorbate 80 is 0.3 mg/mL, 0.4 mg/mL, or 0.5 mg/mL.
Embodiment 4. The liquid pharmaceutical composition of embodiment 1, comprising 1. 1 mg/mL recombinant human factor VIIa, 1.32 mg/mL glycylglycine, 2.34 mg/mL sodium chloride, 1.47 mg/mL calcium chloride dihydrate, 25 mg/mL mannitol, 10 mg/mL sucrose, 0.5 mg/mL methionine, and 0.45-0.75 mg/mL polysorbate 80.
Embodiment 5. The liquid pharmaceutical composition of embodiment 4, the concentration of polysorbate 80 is 0.45 mg/mL, 0.6 mg/mL, or 0.75 mg/mL.
Embodiment 6. The liquid pharmaceutical composition according to any of embodiments 1-5, which is histidine-free.
Embodiment 7. The liquid pharmaceutical composition according to any of embodiments 1-5, further comprising histidine.
Embodiment 8. The liquid pharmaceutical composition of embodiment 7, wherein the histidine is at a concentration of 10 mM.
Embodiment 9. The liquid pharmaceutical composition according to any of embodiments 1-8, having a pH of 6.0.+ -. 0.5.
Embodiment 10. A lyophilized formulation obtained from the liquid pharmaceutical composition of any one of embodiments 1-9 after lyophilization or the lyophilized formulation may be reconstituted to form the liquid pharmaceutical composition of any one of embodiments 1-9.
Embodiment 11. A pharmaceutical composition comprising 1 mg recombinant human factor viia, 1.32. 1.32 mg glycylglycine, 2.34. 2.34 mg sodium chloride, 1.47. 1.47 mg calcium chloride dihydrate, 25. 25 mg mannitol, 10 mg sucrose, 0.5 mg methionine, and 0.45-0.75 mg polysorbate 80.
Embodiment 12. The pharmaceutical composition of embodiment 11, the polysorbate 80 is 0.45 mg, 0.6 mg, or 0.75 mg.
Embodiment 13. The pharmaceutical composition according to any of embodiments 11-12, having a pH of 6.0.+ -. 0.5.
Embodiment 14. Use of the liquid pharmaceutical composition according to any of embodiments 1-9, the lyophilized formulation of embodiment 10 or the pharmaceutical composition of any of embodiments 11-13 in the manufacture of a medicament for preventing or treating bleeding in a subject.
Embodiment 15 use of the liquid pharmaceutical composition according to any of embodiments 1-9, the lyophilized formulation of embodiment 10 or the pharmaceutical composition of any of embodiments 11-13 for the manufacture of a medicament for the treatment of congenital hemophilia patients with inhibitors of blood coagulation factor viii or ix > 5 Bethesda Units (BU), congenital hemophilia patients expected to have a high memory response to injection of blood coagulation factor viii or ix, acquired hemophilia patients, congenital blood coagulation factor vii (vii) deficiency patients, or patients with platelet membrane glycoprotein iib-iia (GP iib-iia) and/or Human Leukocyte Antigen (HLA) antibodies and previous or now ineffective or poor platelet transfusion in platelet weakness patients, or for the prevention and treatment of bleeding in surgical or invasive procedures.
Embodiment 16. The use according to any of embodiments 14-15, the liquid pharmaceutical composition, lyophilized formulation or pharmaceutical composition is administered intravenously to a subject.
Embodiment 17 an article of manufacture comprising a vial containing the pharmaceutical composition of any one of embodiments 11-13.
Embodiment 18 the article of embodiment 17, further comprising a prefilled needle containing a histidine solution.
Embodiment 19 the article of manufacture of any of embodiments 17-18, further comprising instructions for administering recombinant human factor VIIa to a subject to prevent or treat bleeding.
Embodiment 20 the article of any one of embodiments 18-19, wherein the dose of histidine is 1.55 mg.
Embodiment 21 the article of any one of embodiments 18-20, wherein the histidine is at a concentration of 10 mM.
Embodiment 22. The liquid pharmaceutical composition according to any of embodiments 1-9 or the pharmaceutical composition according to any of embodiments 11-13, wherein the recombinant human factor VIIa comprises the sequences shown in SEQ ID NO. 2 and/or SEQ ID NO. 3.
EXAMPLE 1 Effect of different concentrations of Polysorbate 80 in pharmaceutical compositions on colloidal stability
Compositions are prepared from a large number of solutions of purified recombinant human factor VIIa, surfactants and other stabilizers are added, and the solution is diluted to the desired recombinant human factor VIIa concentration. Compositions containing different concentrations of polysorbate 80 as shown in Table 1 were prepared, compositions numbered F1-F5 contained fixed concentrations of recombinant human factor VIIa (0.67 mg/mL), glycylglycine (0. 0.88 mg/mL), sodium chloride (1.56 mg/mL), calcium chloride dihydrate (0.98 mg/mL), mannitol (16.7 mg/mL), sucrose (6.7 mg/mL), methionine (0.33 mg/mL) and different concentrations of polysorbate 80, the composition pH was 6.0.+ -. 0.5.
Table 1 concentration of polysorbate 80 in the compositions
Tagg (Aggregation Temperature ) detection: when the protein solution is subjected to heat treatment, the protein molecules in the solution gradually change from the folded state of the peptide chain to the stretched or unfolded state of the peptide chain (it is also possible that the folding of the individual domains of the protein molecules is opened); it is generally believed that the higher the thermal denaturation temperature, the more stable the protein molecule. Tagg refers to the initial phase of the aggregation behavior of protein molecules that begins during heating of a protein solution.
The Tagg detection method comprises the following steps: the Tagg of the samples was measured using Dynapro Plate Reader iii (Wyatt), the samples were added to 384 well sample trays, the plates were sealed, the 384 well sample trays were centrifuged to remove air bubbles, and the measurement was performed as follows: the temperature program was from 25℃to 85℃and the scan time was 5 seconds.
Colloidal stability was assessed by comparing Tagg of the different composition solutions. Tagg test results for different composition solutions are shown in Table 2. The results show that after the concentration of polysorbate 80 in the composition is increased, the colloidal stability of the composition solution is obviously improved.
TABLE 2 composition solution Tagg
EXAMPLE 2 Effect of different levels of Polysorbate 80 in pharmaceutical compositions on shaking stability
Compositions containing polysorbate 80 at various concentrations were prepared as described in example 1, and solutions of the above compositions were packaged into sterile glass vials at 1.5mL per vial containing fixed amounts of recombinant human factor VIIa (1 mg), glycylglycine (1.32 mg), sodium chloride (2.34 mg), calcium chloride dihydrate (1.47 mg), mannitol (25 mg), sucrose (10 mg), methionine (0.5 mg) and polysorbate 80 after secondary filtration using a 0.22 μm sterile filter membrane in an ultra clean bench. The polysorbate 80 content of the F1-F5 composition is shown in Table 3.
Table 3 polysorbate 80 content in the composition
Vials of the different compositions were shaken at 250 rpm and sampled at 1 and 3 minutes to detect visible foreign matter in the solution and size exclusion chromatography (SEC-HPLC) polymers to compare the shaking stability of the different compositions.
SEC-HPLC assay method: a Waters ACQUITY UPLC Protein BEH SEC Column (200 a, 1.7 μm,4.6 mm ×300× 300 mm) column was used, the pre-column being Waters ACQUITY UPLC Protein BEH SEC Guard Column (200 a, 1.7 μm,4.6 mm ×30 mm); the column temperature is not controlled; the mobile phase is 50 mmol/L phosphate-200 mmol/L sodium chloride solution; the flow rate is 0.3 mL/min; isocratic elution for 20 minutes; the ultraviolet detection wavelength was 215 nm. Taking 10 mug of each of the test sample solution and the physicochemical reference substance solution, and injecting the protein into a liquid chromatograph. The results were analyzed using an area normalization method.
The visible foreign matter and SEC-HPLC polymer detection results for the different composition solutions are shown in tables 4 and 5. After the content of polysorbate 80 is increased, the higher the content of polysorbate 80 in the composition, the less visible foreign matter is generated after shaking. The increase in polysorbate 80 content significantly inhibited the particle growth caused by shaking. Meanwhile, compared with the composition before shaking, the polymer content of the composition solution is increased after shaking, the SEC polymer increase amplitude of F3-F5 is smaller than that of F1, and the SEC polymer increase amplitude of F5 is minimum.
TABLE 4 visible foreign matter results for composition solutions
Note that: indicating that no visible foreign bodies were recorded anymore due to turbidity of the sample.
Table 5 results of SEC polymers before and after shaking of the composition solution
EXAMPLE 3 Effect of different Polysorbate 80 levels in pharmaceutical compositions on the stability of lyophilized finished products
1.5mL of the composition F1 and F5 per bottle was prepared as described in example 2. The samples in the vials were lyophilized and sealed with an aluminum plastic combination cap. The final product was placed at 25 ℃ and 40 ℃ and the stability of the lyophilized final product of each composition was compared. At the time points shown in Table 7, the lyophilized product was reconstituted with 1 mL histidine solution (10 mmol/L) to give compositions F1a and F5a, with the following concentrations of each component in F1a and F5 a: recombinant human factor VIIa (1 mg/mL), glycylglycine (1.32 mg/mL), sodium chloride (2.34 mg/mL), calcium chloride dihydrate (1.47 mg/mL), mannitol (25 mg/mL), sucrose (10 mg/mL), methionine (0.5 mg/mL), polysorbate 80 and histidine (1.55 mg/mL), the concentration of polysorbate 80 in the reconstituted solution is shown in Table 6, and the pH of the reconstituted solution is 6.0.+ -. 0.5.
TABLE 6 concentration of polysorbate 80 in reconstituted solution
The stability of the polysorbate 80 compositions with different contents was evaluated by SEC detection of the polymers by taking the redissolved solutions and the detection results are shown in table 7. The SEC-HPLC multimer detection showed that F1a multimer increased by 0.87% and F5a multimer increased by 0.15% by less than F1a when left at 40℃for 3 months.
The SEC-HPLC dimer/oligomer detection showed that F1a dimer/oligomer increased by 0.43% and F5a multimer increased by 0.1% by less than F1a when left at 40℃for 3 months.
The above results indicate that the stability of F5a is higher.
TABLE 7 stability of Polysorbate 80 compositions of varying levels
/>
Claims (21)
1. A liquid pharmaceutical composition comprising 0.67-1 mg/mL recombinant human factor viia, 0.88-1.32 mg/mL glycylglycine, 1.56-2.34 mg/mL sodium chloride, 0.98-1.47 mg/mL calcium chloride dihydrate, 16.7-25 mg/mL mannitol, 6.7-10 mg/mL sucrose, 0.33-0.5 mg/mL methionine, and 0.3-0.75 mg/mL polysorbate 80.
2. The liquid pharmaceutical composition of claim 1, comprising 0.67 mg/mL recombinant human factor viia, 0.88 mg/mL glycylglycine, 1.56 mg/mL sodium chloride, 0.98 mg/mL calcium chloride dihydrate, 16.7 mg/mL mannitol, 6.7 mg/mL sucrose, 0.33 mg/mL methionine, and 0.3-0.5 mg/mL polysorbate 80.
3. The liquid pharmaceutical composition of claim 2, wherein the concentration of polysorbate 80 is 0.3 mg/mL, 0.4 mg/mL, or 0.5 mg/mL.
4. The liquid pharmaceutical composition of claim 1, comprising 1. 1 mg/mL recombinant human factor viia, 1.32 mg/mL glycylglycine, 2.34 mg/mL sodium chloride, 1.47 mg/mL calcium chloride dihydrate, 25 mg/mL mannitol, 10 mg/mL sucrose, 0.5 mg/mL methionine, and 0.45-0.75 mg/mL polysorbate 80.
5. The liquid pharmaceutical composition of claim 4, wherein the concentration of polysorbate 80 is 0.45 mg/mL, 0.6 mg/mL, or 0.75 mg/mL.
6. The liquid pharmaceutical composition according to any one of claims 1-5, characterized in that it is histidine-free.
7. The liquid pharmaceutical composition of any one of claims 1-5, further comprising histidine.
8. The liquid pharmaceutical composition of claim 7, wherein the histidine is at a concentration of 10 mM.
9. The liquid pharmaceutical composition of claim 1, wherein the pH is 6.0±0.5.
10. A lyophilized formulation, characterized in that it is obtained from the liquid pharmaceutical composition according to any one of claims 1-9 after lyophilization or that the lyophilized formulation can be reconstituted to form the liquid pharmaceutical composition according to any one of claims 1-9.
11. A pharmaceutical composition comprising 1. 1 mg recombinant human factor vila, 1.32. 1.32 mg glycylglycine, 2.34. 2.34 mg sodium chloride, 1.47. 1.47 mg calcium chloride dihydrate, 25. 25 mg mannitol, 10 mg sucrose, 0.5 mg methionine, and 0.45-0.75 mg polysorbate 80.
12. The pharmaceutical composition of claim 11, wherein the polysorbate 80 is 0.45 mg, 0.6 mg or 0.75 mg.
13. The pharmaceutical composition according to any one of claims 11-12, wherein the pH is 6.0±0.5.
14. Use of a liquid pharmaceutical composition according to any one of claims 1-9, a lyophilized formulation according to claim 10 or a pharmaceutical composition according to any one of claims 11-13 in the manufacture of a medicament for preventing or treating bleeding in a subject.
15. Use of a liquid pharmaceutical composition according to any one of claims 1-9, a lyophilized formulation according to claim 10 or a pharmaceutical composition according to any one of claims 11-13 for the manufacture of a medicament for the treatment of congenital hemophilia patients with inhibitors of blood coagulation factor viii or ix > 5 Bethesda units, congenital hemophilia patients expected to have a high memory response to injection of blood coagulation factor viii or ix, acquired hemophilia patients, congenital hemophilia vii deficiency patients bleeding, or for the prevention and treatment of surgical or invasive procedure bleeding.
16. The use according to any one of claims 14-15, wherein the liquid pharmaceutical composition, lyophilized formulation or pharmaceutical composition is administered intravenously to a subject.
17. An article of manufacture comprising a vial containing the pharmaceutical composition of any one of claims 11-13.
18. The article of manufacture of claim 17, further comprising a prefilled needle containing a histidine solution.
19. The article of manufacture of claim 18, wherein the histidine is at a dose of 1.55 mg.
20. The article of manufacture of claim 18, wherein the histidine is at a concentration of 10 mM.
21. The liquid pharmaceutical composition according to claim 1 or the pharmaceutical composition according to claim 11, wherein the recombinant human factor vila comprises the sequence shown in SEQ ID No. 2 and/or SEQ ID No. 3.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410278314.1A CN117860874B (en) | 2024-03-12 | 2024-03-12 | Pharmaceutical composition of recombinant human coagulation factor VIIa |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410278314.1A CN117860874B (en) | 2024-03-12 | 2024-03-12 | Pharmaceutical composition of recombinant human coagulation factor VIIa |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117860874A true CN117860874A (en) | 2024-04-12 |
CN117860874B CN117860874B (en) | 2024-07-02 |
Family
ID=90584871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410278314.1A Active CN117860874B (en) | 2024-03-12 | 2024-03-12 | Pharmaceutical composition of recombinant human coagulation factor VIIa |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117860874B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU94032143A (en) * | 1992-10-02 | 1996-08-20 | Каби Фармациа АБ (SE) | Composition containing the preparation of coagulation factor viii, method of its preparing and the use of surface-active substance as stabilizing agent |
US20040248793A1 (en) * | 2002-06-21 | 2004-12-09 | Jensen Michael Bech | Stabilised solid compositions of factor VII polypeptides |
CN101466400A (en) * | 2006-04-07 | 2009-06-24 | 诺沃-诺迪斯克保健股份有限公司 | Covalent factor VII-tissue factor complex |
WO2010149907A1 (en) * | 2009-06-26 | 2010-12-29 | Lfb-Biotechnologies | Factor vii composition |
AU2012213951A1 (en) * | 2005-04-28 | 2012-09-06 | Novo Nordisk Health Care Ag | A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit |
-
2024
- 2024-03-12 CN CN202410278314.1A patent/CN117860874B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU94032143A (en) * | 1992-10-02 | 1996-08-20 | Каби Фармациа АБ (SE) | Composition containing the preparation of coagulation factor viii, method of its preparing and the use of surface-active substance as stabilizing agent |
US20040248793A1 (en) * | 2002-06-21 | 2004-12-09 | Jensen Michael Bech | Stabilised solid compositions of factor VII polypeptides |
AU2012213951A1 (en) * | 2005-04-28 | 2012-09-06 | Novo Nordisk Health Care Ag | A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit |
CN101466400A (en) * | 2006-04-07 | 2009-06-24 | 诺沃-诺迪斯克保健股份有限公司 | Covalent factor VII-tissue factor complex |
WO2010149907A1 (en) * | 2009-06-26 | 2010-12-29 | Lfb-Biotechnologies | Factor vii composition |
Non-Patent Citations (1)
Title |
---|
刘小利, 罗祖明: "脑出血的止血治疗", 华西医学, no. 01, 30 March 2005 (2005-03-30) * |
Also Published As
Publication number | Publication date |
---|---|
CN117860874B (en) | 2024-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11633462B2 (en) | Pharmaceutical composition comprising plasminogen and uses thereof | |
JP3701028B2 (en) | How to obtain high purity von Willebrand factor | |
JP5357391B2 (en) | Stabilized formulation for immunoglobulin G composition in liquid and lyophilized form | |
FI85334C (en) | Process for Preparation of an Aqueous Tissue Plasminogenic Tivator (t-PA) Containing Concentrated Parent Solution | |
FI85335B (en) | FOERFARANDE FOER FRAMSTAELLNING AV LYOFILISERAD, FARMACEUTISK VAEVNADSPLASMINOGENAKTIVATOR (T-PA) -KOMPOSITION. | |
US9968662B2 (en) | Factor VII composition | |
EP2114379A2 (en) | Factor vii and viia compositions | |
CN114642729B (en) | Coagulation factor X activator composition | |
TW202310873A (en) | Pharmaceutical composition comprising anti-human tslp receptor antibody | |
RU2476235C2 (en) | Compositions of biocompatible microparticles of alginic acid for regulated release of active ingredients in intravenous introduction | |
CN117860874B (en) | Pharmaceutical composition of recombinant human coagulation factor VIIa | |
CA2722230C (en) | Dry transglutaminase composition | |
CN110087689B (en) | Liquid human fibrinogen compositions | |
JP3822383B2 (en) | Soluble thrombomodulin-containing composition | |
RU2814332C1 (en) | Method for cryopreservation of intermediate product of blood coagulation factor viii | |
KR20240044450A (en) | Fibrinogen composition and manufacturing method | |
CN116688103A (en) | Method for shortening freeze-dried fibrinogen reconstitution time and freeze-dried fibrinogen product | |
FR3053592A1 (en) | STABLE LIQUID FIBRINOGEN | |
Chaubal | Novel polymers with enhanced hydrophilicity for the sustained delivery of therapeutic proteins | |
BR112017012972B1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING PLASMINOGEN AND ITS USES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |